AR032756A1 - Metodo de tratamiento para inhibir el progreso o para aliviar una condicion que se alivia por un antagonista de 5-ht3 o del receptor nicotinico neuronal y uso de 1-amino-alquilciclohexanos - Google Patents

Metodo de tratamiento para inhibir el progreso o para aliviar una condicion que se alivia por un antagonista de 5-ht3 o del receptor nicotinico neuronal y uso de 1-amino-alquilciclohexanos

Info

Publication number
AR032756A1
AR032756A1 ARP010102918A ARP010102918A AR032756A1 AR 032756 A1 AR032756 A1 AR 032756A1 AR P010102918 A ARP010102918 A AR P010102918A AR P010102918 A ARP010102918 A AR P010102918A AR 032756 A1 AR032756 A1 AR 032756A1
Authority
AR
Argentina
Prior art keywords
disorders
condition
group
inhibit
antagonist
Prior art date
Application number
ARP010102918A
Other languages
English (en)
Original Assignee
Merz Pharma Gmbh & Co Kgaa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merz Pharma Gmbh & Co Kgaa filed Critical Merz Pharma Gmbh & Co Kgaa
Publication of AR032756A1 publication Critical patent/AR032756A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/34—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton
    • C07C211/35—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton containing only non-condensed rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Otolaryngology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Método para tratar a un animal vivo para inhibir el progreso o para aliviar una condicion que se alivia por un antagonista de 5-HT3 o del receptor nicotínico neuronal, que comprende el paso de administrar a dicho animal vivo una cantidad de un compuesto 1-aminoalquilciclohexano que se selecciona entre el grupo que consiste en aquéllos que tienen la formula (1), donde R* es-(CH2)n-(CR6R7)m-NR8R9, donde n + m = 0, 1, o 2, donde desde R1 hasta R7 se seleccionan independientemente entre el grupo que consiste en hidrogeno y alquilo inferior C1-6, donde R8 y R9 se seleccionan independientemente entre el grupo que consiste en hidrogeno y alquilo inferior C1-6 o juntos representan alquileno inferior -(CH2)x-donde x es 2 a 5, inclusive, e isomeros opticos, enantiomeros, hidrato, y sales aceptables para uso farmacéutico de los mismos, que es efectivo para dicho proposito. Estos 1-aminoalquilciclohexanos son antagonistas del receptor nicotínico y 5-HT3 sistemáticamente activos y son utiles para inhibir el progreso o para aliviar condiciones que se producen por alteraciones de la transmision serotoninérgica o nicotinérgica, con lo cual despliegan un amplio rango de utilidad para el tratamiento de trastornos del sistema nervioso central. Preferiblemente, la condicion alivianada o inhibida se selecciona entre el grupo que consiste en emesis, trastornos de ansiedad, esquizofrenia, trastornos por abuso de drogas y alcohol, trastornos depresivos, trastornos cognitivos, enfermedad de Alzheimer, temblor cerebeloso, enfermedad de Parkinson, mal de Tourette, y trastornos del apetito. Uso de 1-amino-alquilciclohexanos incluyendo sus isomeros opticos, enantiomeros, hidratos, y sales aceptables para uso farmacéutico de los mismos, en la fabricacion de un medicamento para tratar un animal vivo para inhibir la progresion de o aliviar una condicion que se alivia mediante un antagonista del receptor 5-HT3.
ARP010102918A 2000-06-20 2001-06-19 Metodo de tratamiento para inhibir el progreso o para aliviar una condicion que se alivia por un antagonista de 5-ht3 o del receptor nicotinico neuronal y uso de 1-amino-alquilciclohexanos AR032756A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US59710200A 2000-06-20 2000-06-20

Publications (1)

Publication Number Publication Date
AR032756A1 true AR032756A1 (es) 2003-11-26

Family

ID=24390098

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010102918A AR032756A1 (es) 2000-06-20 2001-06-19 Metodo de tratamiento para inhibir el progreso o para aliviar una condicion que se alivia por un antagonista de 5-ht3 o del receptor nicotinico neuronal y uso de 1-amino-alquilciclohexanos

Country Status (21)

Country Link
US (2) US20070105961A1 (es)
EP (2) EP1303477A2 (es)
JP (1) JP4159351B2 (es)
KR (1) KR100570374B1 (es)
CN (1) CN1307147C (es)
AR (1) AR032756A1 (es)
AU (2) AU8186101A (es)
CA (1) CA2410852C (es)
CZ (1) CZ2003497A3 (es)
EA (1) EA006067B1 (es)
GE (1) GEP20053431B (es)
HK (1) HK1076276A1 (es)
HU (1) HUP0301551A3 (es)
IL (2) IL153480A0 (es)
MX (1) MXPA02012244A (es)
NO (1) NO329491B1 (es)
PL (1) PL359583A1 (es)
TW (1) TW593223B (es)
UA (1) UA74194C2 (es)
WO (1) WO2001098253A2 (es)
ZA (1) ZA200104187B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0000540D0 (sv) 2000-02-18 2000-02-18 Astrazeneca Ab New compounds
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
TW200306189A (en) 2002-03-21 2003-11-16 Merz Pharma Gmbh & Co Kgaa Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexane NMDA, 5HT3, and neuronal nicotinic receptor antagonists
PL376476A1 (en) * 2002-10-24 2005-12-27 Merz Pharma Gmbh & Co.Kgaa Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
KR20060030469A (ko) 2003-05-27 2006-04-10 포레스트 래보러토리즈, 인코포레이티드 우울증 및 그 밖의 기분장애의 치료를 위한 ｎｍｄａ수용체 길항제 및 선택적 세로토닌 재흡수 억제제의 배합물
WO2005009421A2 (en) * 2003-07-28 2005-02-03 Merz Pharma Gmbh & Co. Kgaa The use of 1-amino-alkylcyclohexane compounds in the treatment of pain hypersensitivity
AR046314A1 (es) * 2003-11-05 2005-11-30 Merz Pharma Gmbh & Co Kgaa Composiciones que comprenden ciclohexilaminas y aminoadamantanos
TW200531680A (en) * 2004-03-03 2005-10-01 Merz Pharma Gmbh & Co Kgaa Therapy using 1-aminocyclohexane derivatives for the treatment of behavioral disorders associated with alzheimer's disease
EA011290B1 (ru) * 2004-06-17 2009-02-27 Мерц Фарма Гмбх Унд Ко. Кгаа Препаративные формы пероральных лекарственных форм мемантина с немедленным высвобождением
WO2006078239A1 (en) 2005-01-18 2006-07-27 University Of Florida Compositions and methods for inhibiting pain
CA2894860C (en) 2008-11-19 2018-11-06 Gerhard Koenig Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
CN102159201A (zh) 2008-12-19 2011-08-17 莫茨药物股份两合公司 用于治疗肥大细胞介导的疾病的1-氨基-烷基环己烷衍生物
TWI432188B (zh) * 2008-12-19 2014-04-01 Merz Pharma Gmbh & Co Kgaa 供治療發炎性皮膚疾病之１－胺基－烷基環己烷衍生物類
KR101495978B1 (ko) 2010-05-17 2015-02-25 포럼 파마슈티칼즈 인크. (R)-7-클로로-N-(퀴누클리딘-3-일)벤조[b]티오펜-2-카르복사미드 히드로클로리드 모노히드레이트의 결정질 형태
EP3461481A1 (en) 2012-05-08 2019-04-03 Forum Pharmaceuticals Inc. Methods of maintaining, treating or improving cognitive function

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9411955D0 (en) * 1994-06-15 1994-08-03 Merck Sharp & Dohme Therapeutic agents
US5886051A (en) * 1995-11-08 1999-03-23 University Of Florida Research Foundation, Inc. Methods and compositions for the treatment of neurodegeneration
ZA9610738B (en) * 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof
US5728728A (en) * 1996-04-10 1998-03-17 Kozachuk; Walter E. Methods of providing neuroprotection
US6436946B1 (en) * 1997-05-02 2002-08-20 Morris A. Mann Xanthine-containing compositions for oral administration and uses related thereto
US5866585A (en) * 1997-05-22 1999-02-02 Synchroneuron, Llc Methods of treating tardive dyskinesia using NMDA receptor antagonists
US6071966A (en) * 1997-06-30 2000-06-06 Merz + Co. Gmbh & Co. 1-amino-alkylcyclohexane NMDA receptor antagonists
JP3963488B2 (ja) * 1997-06-30 2007-08-22 メルツ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツンク ウント コンパニー コマンディゲゼルシャフト アウフ アクチェン １−アミノ−アルキルシクロヘキサンｎｍｄａ受容体拮抗薬
AR016212A1 (es) * 1998-04-28 2001-06-20 Astra Ab Uso de compuestos farmaceuticos que tienen una actividad antagonista de nmda para preparar un medicamento para el tratamiento del sindrome de intestino irritable (ibs), y composiciones farmaceuticas
US6139861A (en) * 1999-01-14 2000-10-31 Friedman; Mark Intraoral topical anti-inflammatory treatment for relief of migraine, tension-type headache, post-traumatic headache facial pain, and cervical-muscle spasm
US6828462B2 (en) * 2001-11-07 2004-12-07 Merz Pharma Gmbh & Co. Kgaa Unsaturated 1-amino-alkylcyclohexane NMDA, 5HT3, and neuronal nicotinic receptor antagonists

Also Published As

Publication number Publication date
NO20026103L (no) 2003-02-19
MXPA02012244A (es) 2004-09-06
GEP20053431B (en) 2005-01-25
EP2277850A1 (en) 2011-01-26
AU2001281861B2 (en) 2006-08-17
IL153480A0 (en) 2003-07-06
KR20030053475A (ko) 2003-06-28
HUP0301551A2 (hu) 2003-11-28
NO20026103D0 (no) 2002-12-19
CN1307147C (zh) 2007-03-28
UA74194C2 (uk) 2005-11-15
ZA200104187B (en) 2002-11-22
AU8186101A (en) 2002-01-02
HK1076276A1 (en) 2006-01-13
HUP0301551A3 (en) 2005-04-28
JP4159351B2 (ja) 2008-10-01
NO329491B1 (no) 2010-10-25
EA006067B1 (ru) 2005-08-25
CA2410852A1 (en) 2001-12-27
US20100298442A1 (en) 2010-11-25
EP1303477A2 (en) 2003-04-23
CZ2003497A3 (cs) 2004-08-18
TW593223B (en) 2004-06-21
WO2001098253A3 (en) 2002-04-25
CA2410852C (en) 2007-04-24
KR100570374B1 (ko) 2006-04-24
IL153480A (en) 2007-08-19
PL359583A1 (en) 2004-08-23
CN1620419A (zh) 2005-05-25
US20070105961A1 (en) 2007-05-10
JP2004501130A (ja) 2004-01-15
WO2001098253A2 (en) 2001-12-27
EA200300040A1 (ru) 2003-06-26

Similar Documents

Publication Publication Date Title
AR032756A1 (es) Metodo de tratamiento para inhibir el progreso o para aliviar una condicion que se alivia por un antagonista de 5-ht3 o del receptor nicotinico neuronal y uso de 1-amino-alquilciclohexanos
ECSP056192A (es) 3-fluoro-piperidinas como antagonistas de nmda/nr2b
SE0202134D0 (sv) Therapeutic agents
RU2009103307A (ru) ПРОИЗВОДНЫЕ ИМИДАЗО[1, 2-a]ПИРИДИН-2-КАРБОКСАМИДОВ, ИХ ПОЛУЧЕНИЕ И ПРИМЕНЕНИЕ В ТЕРАПИИ
ATE509929T1 (de) Substituierte tricyclische gamma-carbolineals serotonin-rezeptor-agonisten und antagonisten
PA8609201A1 (es) Piridinonas sustituidas
AR041566A1 (es) Derivados de indol utiles para el tratamiento de enfermedades
MA31373B1 (fr) Composes amino-heterocycliques
SE0104334D0 (sv) Therapeutic agents
MA26904A1 (fr) Aminoalkyl 1-lactames substituees et leur utilisation en tant qu'antagonistes du recepteur muscarinique.
AR058287A1 (es) Derivados de isoquinolina y composicion farmaceutica
BRPI0415657A (pt) derivados de alcanamina de diidrobenzofuranila como agonistas de 5ht2c
AR030507A1 (es) Compuesto de pirazolopiridina y los usos farmaceuticos del mismo
RU2009103300A (ru) Производные 2-бензоилимидазопиридинов, их получение и их применение в терапии
ECSP088967A (es) Agonistas del receptor muscarínico que son efectivos en el tratamiento del dolor, la enfermedad de alzheimer y la esquizofrenia
PL361282A1 (en) Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists
UY30377A1 (es) Inhibidores triciclicos fusionados de sulfonamida de gama-secretasa
UY28815A1 (es) Agentes terapéuticos
HRP20110333T1 (hr) 4[(3-fluorfenoksi)fenilmetil]piperidin-metansulfonat: upotreba, postupci sinteze i farmaceutski pripravci
PE20030718A1 (es) Lactamas como antagonistas de taquiquininas
MA46229B1 (fr) Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2
UY26919A1 (es) Derivados de la quinazolina como antagonistas adrenérgicos alfa - 1
PE20191646A1 (es) Derivados pirazol [1,5-a] pirimidina sustituidos con aliciclicos farmacologicamente activos
MXPA04005313A (es) Derivados de aminotetralin como antagonistas del receptor muscarinico.
RU2443697C1 (ru) Замещенные метил-амины, антагонисты серотониновых 5-ht6 рецепторов, способы получения и применения

Legal Events

Date Code Title Description
FB Suspension of granting procedure